ENOB Annual CFO
-$15.73 M
+$4.88 M+23.67%
30 June 2022
Summary:
As of January 21, 2025, ENOB annual cash flow from operations is -$15.73 million, with the most recent change of +$4.88 million (+23.67%) on June 30, 2022. During the last 3 years, it has fallen by -$7.22 million (-84.93%).ENOB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENOB Quarterly CFO
-$3.31 M
+$77.00 K+2.27%
31 March 2023
Summary:
As of January 21, 2025, ENOB quarterly cash flow from operations is -$3.31 million, with the most recent change of +$77.00 thousand (+2.27%) on March 31, 2023. Over the past year, it has dropped by -$523.10 thousand (-18.78%).ENOB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENOB TTM CFO
-$12.56 M
-$523.10 K-4.34%
31 March 2023
Summary:
As of January 21, 2025, ENOB TTM cash flow from operations is -$12.56 million, with the most recent change of -$523.10 thousand (-4.34%) on March 31, 2023. Over the past year, it has increased by +$13.15 million (+51.13%).ENOB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENOB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.7% | -18.8% | +51.1% |
| 3 y3 years | -84.9% | +13.8% | -20.4% |
| 5 y5 years | -1236.1% | -91.0% | -34.6% |
ENOB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | >+9999.0% | >+9999.0% | >+9999.0% |
Enochian Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$3.31 M(-2.3%) | -$12.56 M(+4.3%) |
| Dec 2022 | - | -$3.38 M(+20.0%) | -$12.04 M(-9.3%) |
| Sept 2022 | - | -$2.82 M(-7.5%) | -$13.28 M(-15.6%) |
| June 2022 | -$15.73 M(-23.7%) | -$3.05 M(+9.5%) | -$15.73 M(-38.8%) |
| Mar 2022 | - | -$2.78 M(-39.7%) | -$25.71 M(+1.8%) |
| Dec 2021 | - | -$4.62 M(-12.4%) | -$25.26 M(+9.2%) |
| Sept 2021 | - | -$5.28 M(-59.5%) | -$23.13 M(+12.2%) |
| June 2021 | -$20.61 M(+97.1%) | -$13.03 M(+458.9%) | -$20.61 M(+109.7%) |
| Mar 2021 | - | -$2.33 M(-6.6%) | -$9.83 M(-13.3%) |
| Dec 2020 | - | -$2.50 M(-9.4%) | -$11.34 M(-0.7%) |
| Sept 2020 | - | -$2.76 M(+22.7%) | -$11.41 M(+9.1%) |
| June 2020 | -$10.46 M(+22.9%) | -$2.25 M(-41.5%) | -$10.46 M(+0.3%) |
| Mar 2020 | - | -$3.84 M(+49.1%) | -$10.43 M(+11.8%) |
| Dec 2019 | - | -$2.58 M(+43.0%) | -$9.33 M(+9.6%) |
| Sept 2019 | - | -$1.80 M(-18.8%) | -$8.51 M(+0.0%) |
| June 2019 | -$8.51 M(+96.1%) | -$2.22 M(-19.0%) | -$8.51 M(+7.7%) |
| Mar 2019 | - | -$2.74 M(+56.1%) | -$7.90 M(+14.6%) |
| Dec 2018 | - | -$1.75 M(-2.4%) | -$6.89 M(+22.5%) |
| Sept 2018 | - | -$1.80 M(+11.5%) | -$5.63 M(+29.7%) |
| June 2018 | -$4.34 M(+268.4%) | -$1.61 M(-7.0%) | -$4.34 M(+34.5%) |
| Mar 2018 | - | -$1.73 M(+255.2%) | -$3.23 M(+112.0%) |
| Dec 2017 | - | -$487.70 K(-3.8%) | -$1.52 M(+12.0%) |
| Sept 2017 | - | -$506.90 K(+1.6%) | -$1.36 M(+15.3%) |
| June 2017 | -$1.18 M | -$499.00 K(+1701.4%) | -$1.18 M(+19.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$27.70 K(-91.5%) | -$988.80 K(-5.0%) |
| Dec 2016 | - | -$324.30 K(-0.7%) | -$1.04 M(-24.8%) |
| Sept 2016 | - | -$326.50 K(+5.2%) | -$1.38 M(-6.1%) |
| June 2016 | -$1.47 M(-61.6%) | -$310.30 K(+291.8%) | -$1.47 M(+26.7%) |
| Mar 2016 | - | -$79.20 K(-88.1%) | -$1.16 M(-62.8%) |
| Dec 2015 | - | -$666.80 K(+60.3%) | -$3.13 M(-7.8%) |
| Sept 2015 | - | -$416.00 K(-79.6%) | -$3.39 M(-6.8%) |
| June 2015 | -$3.83 M(+88.3%) | - | - |
| Mar 2015 | - | -$2.04 M(+119.5%) | -$3.64 M(+79.0%) |
| Dec 2014 | -$2.03 M(+6658.1%) | -$931.20 K(+102.0%) | -$2.03 M(+81.7%) |
| Sept 2014 | - | -$461.00 K(+125.8%) | -$1.12 M(+67.5%) |
| June 2014 | - | -$204.20 K(-53.3%) | -$668.40 K(+41.9%) |
| Mar 2014 | - | -$437.70 K(+2505.4%) | -$471.20 K(+1212.5%) |
| Dec 2013 | - | -$16.80 K(+73.2%) | -$35.90 K(+25.1%) |
| Sept 2013 | - | -$9700.00(+38.6%) | -$28.70 K(+10.4%) |
| June 2013 | - | -$7000.00(+191.7%) | -$26.00 K(-13.3%) |
| Mar 2013 | -$30.10 K(+20.9%) | -$2400.00(-75.0%) | -$30.00 K(-7.4%) |
| Dec 2012 | - | -$9600.00(+37.1%) | -$32.40 K(-4.4%) |
| Sept 2012 | - | -$7000.00(-36.4%) | -$33.90 K(+6.6%) |
| June 2012 | - | -$11.00 K(+129.2%) | -$31.80 K(+27.2%) |
| Mar 2012 | -$24.90 K(+23.3%) | -$4800.00(-56.8%) | -$25.00 K(+23.8%) |
| Dec 2011 | -$20.20 K | -$11.10 K(+126.5%) | -$20.20 K(+122.0%) |
| Sept 2011 | - | -$4900.00(+16.7%) | -$9100.00(+116.7%) |
| June 2011 | - | -$4200.00 | -$4200.00 |
FAQ
- What is Enochian Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Enochian Biosciences?
- What is Enochian Biosciences annual CFO year-on-year change?
- What is Enochian Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Enochian Biosciences?
- What is Enochian Biosciences quarterly CFO year-on-year change?
- What is Enochian Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Enochian Biosciences?
- What is Enochian Biosciences TTM CFO year-on-year change?
What is Enochian Biosciences annual cash flow from operations?
The current annual CFO of ENOB is -$15.73 M
What is the all time high annual CFO for Enochian Biosciences?
Enochian Biosciences all-time high annual cash flow from operations is -$20.20 K
What is Enochian Biosciences annual CFO year-on-year change?
Over the past year, ENOB annual cash flow from operations has changed by +$4.88 M (+23.67%)
What is Enochian Biosciences quarterly cash flow from operations?
The current quarterly CFO of ENOB is -$3.31 M
What is the all time high quarterly CFO for Enochian Biosciences?
Enochian Biosciences all-time high quarterly cash flow from operations is -$2400.00
What is Enochian Biosciences quarterly CFO year-on-year change?
Over the past year, ENOB quarterly cash flow from operations has changed by -$523.10 K (-18.78%)
What is Enochian Biosciences TTM cash flow from operations?
The current TTM CFO of ENOB is -$12.56 M
What is the all time high TTM CFO for Enochian Biosciences?
Enochian Biosciences all-time high TTM cash flow from operations is -$4200.00
What is Enochian Biosciences TTM CFO year-on-year change?
Over the past year, ENOB TTM cash flow from operations has changed by +$13.15 M (+51.13%)